Article
Multidisciplinary Sciences
Vamsidhar Velcheti, Xiaohan Hu, Bilal Piperdi, Thomas Burke
Summary: The study demonstrated the effectiveness of first-line pembrolizumab-combination therapy for metastatic nonsquamous NSCLC patients treated at US oncology practices, showing promising clinical outcomes.
SCIENTIFIC REPORTS
(2021)
Article
Oncology
David H. Johnson, Louis Fehrenbacher, William F. Novotny, Roy S. Herbst, John J. Nemunaitis, David M. Jablons, Corey J. Langer, Russell F. DeVore III, Jacques Gaudreault, Lisa A. Damico, Eric Holmgren, Fairooz Kabbinavar
Summary: This study aimed to investigate the efficacy and safety of bevacizumab in combination with carboplatin and paclitaxel for advanced or recurrent non-small-cell lung cancer. The results showed that the addition of bevacizumab improved overall response and time to progression, but bleeding was the most prominent adverse event. Patients with nonsquamous cell histology appeared to have better treatment outcomes and acceptable safety risks.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Oncology
Toshinobu Hayashi, Mototsugu Shimokawa, Koichi Matsuo, Hirotoshi Iihara, Kei Kawada, Takafumi Nakano, Takashi Egawa
Summary: Patients with lung cancer undergoing carboplatin plus pemetrexed (CBDCA+PEM) chemotherapy have a higher risk of delayed nausea compared to those undergoing carboplatin plus paclitaxel (CBDCA+PTX) chemotherapy, while the incidence of vomiting does not significantly differ between the two groups. Female sex, younger age, and CBDCA+PEM regimen are independent risk factors for delayed nausea, while female sex is an independent risk factor for delayed vomiting.
Article
Oncology
T. C. Lam, K. C. Tsang, H. C. Choi, V. H. Lee, K. O. Lam, C. L. Chiang, T. H. So, W. W. Chan, S. F. Nyaw, F. Lim, J. O. Lau, J. Chik, F. M. Kong, A. W. Lee
Summary: This study confirmed the promising efficacy of the combination of atezolizumab, bevacizumab, pemetrexed, and carboplatin in EGFR mutated lung cancer after TKI failure. Treatment-related adverse events were common, but quality of life measures did not change significantly.
Article
Oncology
Yuan Yuan, Susan E. Yost, Yujie Cui, Christopher Ruel, Mireya Murga, Aileen Tang, Norma Martinez, Daniel Schmolze, James Waisman, Niki Patel, Lalit Vora, Lusine Tumyan, Mari Bozoghlanian, Daphne Stewart, Paul H. Frankel
Summary: This trial evaluated the safety and efficacy of ipatasertib in combination with different chemotherapy regimens for metastatic triple-negative breast cancer (mTNBC). The results showed that continuous dosing of ipatasertib with chemotherapy was safe and well-tolerated, and the overall response rates and progression-free survival varied among the different treatment arms. Further study is needed to better understand the role of AKT inhibition in the treatment of TNBCs.
Article
Oncology
Yuan Yuan, Susan E. Yost, Yujie Cui, Christopher Ruel, Mireya Murga, Aileen Tang, Norma Martinez, Daniel Schmolze, James Waisman, Niki Patel, Lalit Vora, Lusine Tumyan, Mari Bozoghlanian, Daphne Stewart, Paul H. Frankel
Summary: This study evaluated the safety and efficacy of ipatasertib in combination with carboplatin, carboplatin/paclitaxel, or capecitabine/atezolizumab in patients with metastatic triple-negative breast cancer (mTNBC). The primary endpoints were safety and recommended phase II dose (RP2D), while secondary endpoints included progression-free survival (PFS), response rate, and overall survival. The results showed that continuous dosing of ipatasertib with chemotherapy was safe and well-tolerated, and further research is needed to understand the role of AKT inhibition in the treatment of TNBC.
Article
Oncology
Melanie Royce, Christy L. Osgood, Anup K. Amatya, Mallorie H. Fiero, C. J. George Chang, Tiffany K. Ricks, Krithika A. Shetty, Jeffrey Kraft, Junshan Qiu, Pengfei Song, Rosane Charlab, Jingyu Yu, Kathryn E. King, Anshu Rastogi, Brian Janelsins, Wendy C. Weinberg, Kathleen Clouse, Vicky Borders-Hemphill, Lindsey Brown, Candace Gomez-Broughton, Zhong Li, Thuy Thanh Nguyen, Zhihao Qiu, Anh-Thy Ly, Suyoung Chang, Tingting Gao, Chi-Ming Tu, Bellinda King-Kallimanis, William F. Pierce, Kelly Chiang, Clara Lee, Kirsten B. Goldberg, John K. Leighton, Shenghui Tang, Richard Pazdur, Julia A. Beaver, Laleh Amiri-Kordestani
Summary: Margetuximab-cmkb in combination with chemotherapy was granted regular FDA approval for the treatment of HER2-positive metastatic breast cancer patients who have received two or more prior anti-HER2 regimens. The SOPHIA study demonstrated that margetuximab had a longer median progression-free survival compared to trastuzumab when both were combined with chemotherapy. Infusion-related reactions were reported as important safety signals associated with margetuximab plus chemotherapy.
CLINICAL CANCER RESEARCH
(2022)
Article
Oncology
Y. Nakamura, K. Namikawa, S. Yoshikawa, Y. Kiniwa, T. Maekawa, O. Yamasaki, T. Isei, S. Matsushita, M. Nomura, Y. Nakai, S. Fukushima, S. Saito, T. Takenouchi, R. Tanaka, H. Kato, A. Otsuka, T. Matsuya, N. Baba, K. Nagase, T. Inozume, N. Fujimoto, Y. Kuwatsuka, M. Onishi, T. Kaneko, T. Onuma, Y. Umeda, D. Ogata, A. Takahashi, M. Otsuka, Y. Teramoto, N. Yamazaki
Summary: In a study of advanced mucosal melanoma patients in Japan, it was found that there was no significant difference in efficacy between PD1 and PD1 + CTLA4, but the latter had a higher incidence of immune-related adverse events.
Article
Oncology
Lecia V. Sequist, James Chih-Hsin Yang, Nobuyuki Yamamoto, Kenneth O'Byrne, Vera Hirsh, Tony Mok, Sarayut Lucien Geater, Sergey Orlov, Chun-Ming Tsai, Michael Boyer, Wu-Chou Su, Jaafar Bennouna, Terufumi Kato, Vera Gorbunova, Ki Hyeong Lee, Riyaz Shah, Dan Massey, Victoria Zazulina, Mehdi Shahidi, Martin Schuler
Summary: The study compared the efficacy of chemotherapy with afatinib in the treatment of EGFR-mutated lung adenocarcinoma. Results showed that afatinib prolonged progression-free survival and improved the quality of life for patients, when compared with chemotherapy.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Oncology
L. Cortesi, M. Venturelli, G. Cortesi, F. Caggia, A. Toss, E. Barbieri, U. De Giorgi, V. Guarneri, A. Musolino, E. De Matteis, A. Zambelli, G. Bisagni, M. Dominici
Summary: In this clinical trial, the efficacy and safety of pembrolizumab plus carboplatin in treating first-line visceral disease BRCA-related luminal breast cancer were investigated. The primary aim of achieving an overall response rate >70% was not met, but further investigation is needed.
Article
Oncology
Caicun Zhou, Gongyan Chen, Yunchao Huang, Jianying Zhou, LiZhu Lin, Jifeng Feng, Zhehai Wang, YongQian Shu, Jianhua Shi, Yi Hu, QiMing Wang, Ying Cheng, Fengying Wu, Jianhua Chen, Xiaoyan Lin, Yongsheng Wang, Jianan Huang, Jiuwei Cui, Lejie Cao, Yunpeng Liu, Yiping Zhang, Yueyin Pan, Jun Zhao, LiPing Wang, Jianhua Chang, Qun Chen, Xiubao Ren, Wei Zhang, Yun Fan, Zhiyong He, Jian Fang, Kangsheng Gu, XiaoRong Dong, Faguang Jin, Hongjun Gao, Guangyu An, Cuimin Ding, Xiaodong Jiang, Jianping Xiong, Xiangdong Zhou, Sheng Hu, Ping Lu, Anwen Liu, Shuliang Guo, Jianjin Huang, Chengchu Zhu, Jian Zhao, Beili Gao, Yinglan Chen, Chengping Hu, Jian Zhang, Hongmei Zhang, Hui Zhao, Yanfei Tai, Xinjing Ma, Wei Shi, CameL Study Grp
Summary: The addition of camrelizumab to first-line chemotherapy significantly improves the progression-free survival of patients with advanced nonsquamous NSCLC. It provides long-term survival benefit with manageable toxicity and durable response. These results support the combination of camrelizumab and chemotherapy as a first-line treatment for advanced nonsquamous NSCLC.
JOURNAL OF THORACIC ONCOLOGY
(2023)
Article
Oncology
Liying Sun, Shenglan Huang, Dan Li, Ye Mao, Yurou Wang, Jianbing Wu
Summary: The study suggests that fruquintinib combined with PD-1 inhibitor may improve progression-free survival time in patients with advanced MSS or pMMR mCRC compared to regorafenib combined with PD-1 inhibitor.
FRONTIERS IN ONCOLOGY
(2021)
Article
Urology & Nephrology
Xiao X. Wei, Lillian Werner, Min Y. Teo, Jonathan E. Rosenberg, Vadim S. Koshkin, Petros Grivas, Bernadett Szabados, Laura Morrison, Thomas Powles, Lucia Carril-Ajuria, Daniel Castellano, Pedro Isaacsson Velho, Noah M. Hahn, Rana R. McKay, Daniele Raggi, Andrea Necchi, Ravindran Kanesvaran, Parissa Alerasool, Jacob Gaines, Matthew Galsky, Joaquim Bellmunt, Guru Sonpavde
Summary: In patients with metastatic urothelial carcinoma, receiving first line PD-1/L1 inhibitors followed by carboplatin containing chemotherapy and the reverse sequence resulted in comparable overall survival.
JOURNAL OF UROLOGY
(2021)
Review
Oncology
Francisco Cezar Aquino de Moraes, Eric Pasqualotto, Lucca Moreira Lopes, Maria Eduarda Cavalcanti Souza, Anna Luiza Soares de Oliveira Rodrigues, Artur Menegaz de Almeida, Carlos Stecca, Marianne Rodrigues Fernandes, Ney Pereira Carneiro dos Santos
Summary: The combination of PD-1/PD-L1 inhibitors with carboplatin and paclitaxel significantly improves progression-free survival and overall survival in patients with advanced or recurrent endometrial cancer, particularly for those with mismatch repair deficiency and high microsatellite instability.
Article
Medicine, General & Internal
Hongkai Lu, Na Wang, Peng Wang, Haolin Zhang, Ru Zhao, Hongju Liu, Xirong He, Zeya Liu, Yue Chang, Yongtong Cao, Shiyao Wang
Summary: This case report describes a patient with non-small cell lung cancer who developed severe immune hemolytic anemia after receiving pemetrexed plus cisplatin chemotherapy. Laboratory findings suggest the presence of complement-dependent pemetrexed antibodies and cisplatin-associated non-immunologic protein adsorption.
FRONTIERS IN MEDICINE
(2022)